{"entity":{"id":"genrix-bio","kind":"company","name":"Genrix Bio","aka":["Genrix (Shanghai) Biopharmaceutical","智翔金泰","SSE:688443"],"tldr":"Genrix Bio is a Shanghai antibody company, listed on the Shanghai STAR market, whose oncology lead GR1803 is a BCMA and CD3 bispecific T-cell engager for multiple myeloma.","summary":"Genrix (Shanghai) Biopharmaceutical, a subsidiary of Zhifei Biological Products, develops monoclonal and bispecific antibodies. Its first approved product is the IL-17A antibody xeligekimab for psoriasis; its pipeline spans autoimmune, infectious and cancer indications. GR1803, a bispecific antibody binding BCMA on myeloma cells and CD3 on T cells, is in a phase 1/2 trial in relapsed or refractory multiple myeloma.","asOf":"2026-09-17","links":[],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["gr1803"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Shanghai","country":"CN","companyType":"biotech","ticker":"SSE:688443","stage":"public","investors":[],"funding":[]},"route":"/companies/genrix-bio/","neighbours":{"drug":[{"id":"gr1803","kind":"drug","name":"GR1803","route":"/drugs/gr1803/"}]}}